Cargando…
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
BACKGROUND: Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab. METHODS: This analysis was conducted on patients with pat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824947/ https://www.ncbi.nlm.nih.gov/pubmed/33482769 http://dx.doi.org/10.1186/s12885-020-07739-8 |